Efficacy, Safety and Tolerance with the Integrase Inhibitors Dolutegravir and Elvitegravir

What is it about?

INSTI (raltegravir, elvitegravir, and dolutegravir) are positioned as preferred options in clinical guidelines. Since we encountered many patients who stopped DTG and EVG/COBI because of adverse events, we analysed the experience with these INSTI in our whole patient population.

Featured Image

Why is it important?

Elvitegravir and dolutegravir have been licensed the latest being available in fixed-dose combinations with a NRTI backbone in one tablet given once daily. We encountered many patients who stopped DTG and EVG/COBI because of adverse events and the occurrence of unexpected discontinuations due side effects of DTG were previously reported in other three recent observational real-life studies. This paper analysed the experience with these INSTI in our whole patient population.